** U.S.-listed shares of Atai Life Sciences 9VC.DE, ATAI.O rise 25% to $2.71 premarket
** Atai and Oxford-based firm Beckley Psytech say their experimental depression drug, BPL-003, met the main goals in a mid-stage study
** Both 8 mg and 12 mg single doses of the drug significantly reduced depressive symptoms compared to a low-dose control at all time points through eight weeks, cos say
** Firms say the trial data support advancing the 8 mg dose into late-stage trial, pending regulatory discussions
** Last month, Atai announced a $390 mln merger with Beckley Psytech to create a combined psychedelic mental health therapy firm
** As of last close, ATAI up 64.7% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。